Videos

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.

If feasible, hypofractionated radiation—large doses of radiation given over a shorter period of time than standard radiation—after mastectomy would provide more patients with breast cancer a tissue-sparing option, according to an expert from the Mayo Clinic.

It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.

A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.

The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.

Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.

Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.

Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.

Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.

A brief review of the role of tagraxofusp as bridging therapy to stem cell transplant in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.

Comprehensive discussion on the management of adverse events associated with tagraxofusp and how BPDCN care can be optimized in the setting of academic centers.

Focused discussion from a panel of key opinion leaders on the presence and management of cytokine release syndrome alongside BCMA-targeted therapy in relapsed/refractory MM.

Shared insight from expert hematologist-oncologists on the real-world application of teclistamab to improve the management of multiple myeloma.

Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.

Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.

The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.

Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.

A brief review of common adverse events inherent in the first-line management of advanced renal cell carcinoma and practical advice on how to mitigate treatment toxicity.

Opening their discussion on the advanced renal cell carcinoma treatment landscape, experts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, identify cornerstone first-line regimens.

An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.

Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.

A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.

Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.

An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.

Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.

A broad perspective on the development of BCMA-targeted bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.

Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.

Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.